"The M&A market has been relatively slow over the past year as pharma executives wait on the sidelines for the valuation correction to play out, but I believe that we will see M&A activities increase in this coming year."
"Nivagen has excellent connections and market access, and we are always looking to in-license FDA-approved products that leverage our expertise in launching in the US market."
"MassBio remains focused on providing the necessary support to help companies succeed so we can continue to stay the best place in the world for life sciences."
"The main trait we are looking for in partners is access to interesting chemical libraries where, combining good chemistry with our platforms, we can identify novel treatments for neuropsychiatric disorders."
"People are realizing that our sector may need to be more discerning in deciding which companies are worthy and mature enough to bring to the public markets."
"Through our growing network of cGMP facilities across Europe and the US, we aim to continue to translate complex processes and projects at any stage of development into high-value products."
"We established a dynamic drug delivery systems (DDS) company focused on providing a range of effective solutions to optimize the delivery of pharmaceutical products."
"AMS was established in Salt Lake City in August 2017 to provide both drilling tools and technical expertise to suit any specific drilling projects needs."
The pre-release edition of Africa Energy 2024 comprises analysis based on over 80 interviews with ministers and leading executives from IOCs, NOCs, independents, associations, investors and service providers, to provide an in-depth and holistic view of sub-Saharan Africa’s ever-evolving energy sector.